Intellectual Property problems for personalized medicine

Patently BIOtech

Amid growing interest in personalized medicine that stands to provide patients with better care at reduced costs, legal battles over gene patents ensue, threatening the viability of widespread implementation. On this topic authors Jennifer Gordon, Steve Lendaris and Anna Volftsun (layers at Baker Botts LLP) wrote a very interesting opinion article for The Scientist on the topic. They also examine the barriers to personalized medicine, including a pending decision in the Myriad Genetics case, and their potential to determine the future of American healthcare.

Patently BIOtech  |  Email This Post  |  Printer Friendly
Tags: , , , , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>